Evolution of the chemotherapeutic landscape and survival outcome in patients with metastatic pancreatic cancer: a four-institute cohort study in Taiwan, 2010–2016

References

• SiegelRLMillerKDJemalACancer statistics, 2018CA Cancer J Clin20186873029313949
   PubMed Web of Science ®Google Scholar
• Health Registry Annual Report 2013. Republic of ChinaRepublic of China: Republic of ChinaBureau of health promotion, department of health, executive Yuan2015 Available from: http://www.hpa.gov.tw/BHPNet/Web/Stat/Statistics.aspxAccessed September 20, 2018
   Google Scholar
• van RijswijkREJeziorskiKWagenerDJWeekly high-dose 5-fluorouracil and folinic acid in metastatic pancreatic carcinoma: a phase II study of the EORTC gastrointestinal tract Cancer Cooperative GroupEur J Cancer200440142077208115341982
   PubMed Web of Science ®Google Scholar
• BurrisHAMooreMJAndersenJImprovements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trialJ Clin Oncol1997156240324139196156
   PubMed Web of Science ®Google Scholar
• MooreMJGoldsteinDHammJErlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupJ Clin Oncol200725151960196617452677
   PubMed Web of Science ®Google Scholar
• ColucciGGiulianiFGebbiaVGemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell’Italia meridionaleCancer20029490291011920457
   PubMed Web of Science ®Google Scholar
• PelzerUSchwanerIStielerJBest supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (off) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study groupEur J Cancer201147111676168121565490
   PubMed Web of Science ®Google Scholar
• ConroyTDesseigneFYchouMFolfirinox versus gemcitabine for metastatic pancreatic cancerN Engl J Med2011364191817182521561347
   PubMed Web of Science ®Google Scholar
• von HoffDDErvinTArenaFPIncreased survival in pancreatic cancer with nab-paclitaxel plus gemcitabineN Engl J Med2013369181691170324131140
   PubMed Web of Science ®Google Scholar
• UenoHIokaTIkedaMRandomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: Gest studyJCO2013311316401648
   PubMed Web of Science ®Google Scholar
• ShirasakaTShimamatoYOhshimoHDevelopment of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulatorsAnticancer Drugs1996755485578862723
   PubMed Web of Science ®Google Scholar
• UenoHOkusakaTIkedaMTakezakoYMorizaneCAn early phase II study of S-1 in patients with metastatic pancreatic cancerOncology2005682–317117816006754
   PubMed Web of Science ®Google Scholar
• OkusakaTFunakoshiAFuruseJA late phase II study of S-1 for metastatic pancreatic cancerCancer Chemother Pharmacol200861461562117520253
   PubMed Web of Science ®Google Scholar
• NakamuraKYamaguchiTIshiharaTSudoKKatoHSaishoHPhase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancerBr J Cancer200694111575157916721372
   PubMed Web of Science ®Google Scholar
• YanagimotoHSatoiSShoMPhase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinomaCancer Chemother Pharmacol2016771354126645403
   PubMed Web of Science ®Google Scholar
• ZhangWduCSunYNab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trialCancer Chemother Pharmacol201882465566030054709
   PubMed Web of Science ®Google Scholar
• QuanHSundararajanVHalfonPCoding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative dataMed Care200543111130113916224307
   PubMed Web of Science ®Google Scholar
• UICC TNMClassification of Malignant Tumours7th edNew YorkWiley & Liss2009
   Google Scholar
• ChouWCWangFChengYFA simple risk stratification model that predicts 1-year postoperative mortality rate in patients with solid-organ cancerCancer Med20154111687169626311149
   PubMed Web of Science ®Google Scholar
• ArmitagePTests for linear trends in proportions and frequenciesBiometrics1955113375386
   Web of Science ®Google Scholar
• National Cancer Institute [homepage on the Internet]Annual percent change (APC) and confidence interval Available from: https://surveillance.cancer.gov/help/joinpoint/setting-parameters/method-and-parameters-tab/apc-aapc-tau-confidence-intervals/estimate-average-percent-change-apc-and-confidence-intervalAccessed September 20, 2018
   Google Scholar
• SultanaASmithCTCunninghamDStarlingNNeoptolemosJPGhanehPMeta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancerJ Clin Oncol200725182607261517577041
   PubMed Web of Science ®Google Scholar
• CrownJCasperESBotetJMurrayPKelsenDPLack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinomaJ Clin Oncol199199168216861875224
   PubMed Web of Science ®Google Scholar
• DeCaprioJAMayerRJGoninRArbuckSGFluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trialJ Clin Oncol1991912212821331960554
   PubMed Web of Science ®Google Scholar
• Di CostanzoFCarliniPDoniLGemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC)Br J Cancer200593218518915986036
   PubMed Web of Science ®Google Scholar
• HessVSalzbergMBornerMCombining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trialJ Clin Oncol2003211666812506172
   PubMed Web of Science ®Google Scholar
• ScheithauerWSchüllBUlrich-PurHBiweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trialAnn Oncol20031419710412488300
   PubMed Web of Science ®Google Scholar
• ColucciGLabiancaRdi CostanzoFRandomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 studyJ Clin Oncol201028101645165120194854
   PubMed Web of Science ®Google Scholar
• HeinemannVQuietzschDGieselerFRandomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancerJ Clin Oncol200624243946395216921047
   PubMed Web of Science ®Google Scholar
• ZhangYDYangQJiangZMMaWZhouSWXieDROverall survival of patients with advanced pancreatic cancer improved with an increase in second-line chemotherapy after gemcitabine-based therapyJOP201112213113721386638
   PubMedGoogle Scholar
• IokaTKomatsuYMizunoNRandomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancerBr J Cancer2017116446447128081543
   PubMed Web of Science ®Google Scholar
• OhkawaSOkusakaTIsayamaHRandomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancerBr J Cancer201511291428143425880004
   PubMed Web of Science ®Google Scholar
• TakaharaNIsayamaHNakaiYA retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancerCancer Chemother Pharmacol201372598599023995699
   PubMed Web of Science ®Google Scholar
• ClinicalTrial.gov [webpage on the Internet]NCT00429858. Gem-citabine and S-1 for locally advanced unresectable or metastatic pancreatic cancer Available from: https://clinicaltrials.gov/ct2/show/NCT00429858?term=s-1&cond=Pancreatic+Cancer+Non-resectable&rank=4Accessed October 20, 2018
   Google Scholar